Protective role of Resveratrol in Heart surgery

Phase 3

Recruiting

• Conditions: Diseases of the circulatory system.; Ischemic heart diseases

• Registration Number: IRCT20111119008129N12
• Lead Sponsor: Boushehr University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Intention of the patients to participate in the trial
Patients on elective surgery
Having no addiction to any drugs or alcohol
Not having mental or psychological disorders
Participants with the age between 30 to 70 years

Exclusion Criteria

History of having chronic kidney disease,
History of having chronic liver disease
Having heart surgery before

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The heart function. Timepoint: Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption. Method of measurement: By echocardiography.;Diastolic blood pressure. Timepoint: Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption. Method of measurement: By sphygmomanometer, Mercury Type ( Microlife company).;Systolic blood pressure. Timepoint: Around 24 hours, before the start of Resveratrol consumption, and 12 to 24 hours after the period of 60 days of consumption. Method of measurement: By sphygmomanometer, Mercury Type ( Microlife company).